Previous 10 | Next 10 |
Hillstream BioPharma ( NASDAQ: HILS ) is trading ~8.2% higher premarket after signing an agreement with Applied Biomedical Science Institute to license technology against drug resistant cancers including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and...
HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against Drug Resistant Breast and Gastric Cancers Anti-HER2 and Anti-HER3 monoclonal antibodies ...
3 Benefits of Holding Penny Stocks Investing in penny stocks can be a great way to build wealth over the long term. Penny stocks are shares of small companies that trade at low prices, often less than $5 per share. This can make them an affordable option for investors who are just startin...
Hillstream BioPharma ( NASDAQ: HILS ) reported initial results from a study evaluating HSB-1216 in combination with Merck' ( NYSE: MRK ) Keytruda (pembrolizumab) in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Calu-1. The company said the study showed significant...
Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Lung cancer remains one of the leading causes of cancer-related deaths worldwide NSCLC accounts for approximately 80–85% of all cases of lung cancer ...
Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ / HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor) BRIDGEWATER, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasd...
Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers HSB-1940, an anti-PD-1 Quatrabody™, is a proprietary targeted IO biologic BRIDGEWATER, N.J., Feb. 06, 2023 (GLOBE NEWSWI...
Development-stage biotech Hillstream BioPharma ( NASDAQ: HILS ) climbed ~107% on Tuesday after announcing an exclusive option agreement with Dana-Farber Cancer Institute for technology linked to oncology gene MUC1. Per the terms, Hillstream ( HILS ) will have the option to con...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: luchschenF / Shutterstock.com It’s not every day that you hear about Hillstream BioPharma (NASDAQ: HILS ) in the financial headlines. Today, however, HILS stock is skyrocketing more than 100% on heavy tra...
A New Jersey-based %Biotech company is turning heads Tuesday morning after the company announced the signing an exclusive option agreement with %DanaFarberCancerInstitute to license technology targeting the MUC1-C oncoprotein. This sent shares of %HillstreamBioPharma ($HILS) soari...
News, Short Squeeze, Breakout and More Instantly...
Hillstream BioPharma Inc. Company Name:
HILS Stock Symbol:
NASDAQ Market:
Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeu...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic prur...